Impact of siponimod on vaccination response in a randomized, placebo-controlled study
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 11, 2017
- Accepted in final form June 23, 2017
- First Published September 14, 2017.
Author Disclosures
- Mike Ufer, MD, PhD,
- Kasra Shakeri-Nejad, MD,
- Anne Gardin, PhD,
- Zhenzhong Su, PhD,
- Ines Paule, PhD,
- Thomas C. Marbury, MD and
- Eric Legangneux, MD
- Mike Ufer, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Employee of Novartis Pharma AG during the study
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Employee of Novartis Pharma AG during the study and entitled for stock options
NONE
NONE
NONE
NONE
NONE
- Kasra Shakeri-Nejad, MD,
NONE
NONE
NONE
NONE
NONE
NONE
1) Novartis Institutes for Biomedical Research, Basel, Switzerland, Director Senior Translational Medicine Expert, 2011-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anne Gardin, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Novartis Pharma AG (2001- to date)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Zhenzhong Su, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Contributed to the study/manuscript as employee of Novartis Pharma AG
NONE
NONE
NONE
NONE
Contributed to the study/manuscript as employee of Novartis Pharma AG
NONE
NONE
NONE
Contributed to the study/manuscript as employee of Novartis Pharma AG and was entitled for stock or stock options
NONE
NONE
NONE
NONE
NONE
- Ines Paule, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Employee of Novartis Pharma AG during the study
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Employee of Novartis Pharma AG during the study and entitled for stock options.
NONE
NONE
NONE
NONE
NONE
- Thomas C. Marbury, MD and
NONE
NONE
NONE
NONE
NONE
NONE
Employee and equity owner of Orlando Clinical Research Center since 1990 as President
NONE
NONE
NONE
NONE
Orlando Clinical Research was contracted to enroll and study subjects for this study.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eric Legangneux, MD
NONE
NONE
NONE
NONE
NONE
NONE
Employee of Novartis Pharma AG
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Employee of Novartis Pharma AG . Entitled for stock options
NONE
NONE
NONE
NONE
NONE
- From the Novartis Pharma AG (M.U., K.S.-N., A.G., Z.S., I.P., E.L.), Basel, Switzerland; and Orlando Clinical Research Center (T.C.M.), Orlando, FL.
- Correspondence to Dr. Ufer: mikeufer{at}gmx.de
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosisThe VELOCE studyAmit Bar-Or, Jonathan C. Calkwood, Cathy Chognot et al.Neurology, July 29, 2020 -
Article
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosisLudwig Kappos, Matthias Mehling, Rafael Arroyo et al.Neurology, January 30, 2015 -
Research
Uptake and Attitudes About Immunizations in People With Multiple SclerosisRuth Ann Marrie, Leanne Kosowan, Gary R. Cutter et al.Neurology: Clinical Practice, April 22, 2021 -
Articles
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosisM. Mehling, T.A. Johnson, J. Antel et al.Neurology, February 21, 2011